Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Pancreatic Neoplasms 4Sarcoma 2Neoplasm Metastasis 2Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Melanoma 1Glioma 1Glioblastoma 1

Interventions

Temozolomide 115Bevacizumab 72Radiotherapy 52Radiation 23Erlotinib Hydrochloride 13Lomustine 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Vorinostat 10Nivolumab 10Surgical Procedures, Operative 9Irinotecan 9Sorafenib 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 7Immunoglobulin G 7Everolimus 7Drug Therapy 7Disulfides 7Radiosurgery 6Granulocyte-Macrophage Colony-Stimulating Factor 6Carmustine 6antineoplaston AS 2-1 5antineoplaston A10 5Sirolimus 5Cilengitide 5veliparib 4veledimex 4temsirolimus 4selinexor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Glioblastoma × TH 302 × Clear all
NCT02342379 2020-04-10

TH-302 in Combination With Bevacizumab for Glioblastoma

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
35 enrolled 6 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡